Effects of aspirin for primary prevention in persons with diabetes mellitus

New England Journal of Medicine

Volumn 379, Issue 16, 2018, Pages 1529-1539

  Bowman, Louise ^a   Mafham, Marion ^a   Wallendszus, Karl ^a   Stevens, Will ^a   Buck, Georgina ^a   Barton, Jill ^a   Murphy, Kevin ^a   Aung, Theingi ^a   Haynes, Richard ^a   Cox, Jolyon ^a   Murawska, Aleksandra ^a   Young, Allen ^a   Lay, Michael ^a   Chen, Fang ^a   Sammons, Emily ^a   Waters, Emma ^a   Adler, Amanda ^a   Bodansky, Jonathan ^a   Farmer, Andrew ^a   McPherson, Roger ^a   Neil, Andrew ^a   Simpson, David ^a   Peto, Richard ^a   Baigent, Colin ^a   Collins, Rory ^a   Parish, Sarah ^a   Armitage, Jane ^a   more..

^a CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OMEGA 3 FATTY ACID; PLACEBO; ANTITHROMBOCYTIC AGENT;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CANCER RISK; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETES MELLITUS; DIGESTIVE SYSTEM CANCER; DIGESTIVE SYSTEM PERFORATION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EPISTAXIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEMATURIA; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSIENT ISCHEMIC ATTACK; UPPER GASTROINTESTINAL BLEEDING; CHEMICALLY INDUCED; CLINICAL TRIAL; DIABETIC COMPLICATION; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY; POISSON DISTRIBUTION; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ASPIRIN; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POISSON DISTRIBUTION; PRIMARY PREVENTION; RISK FACTORS;

EID: 85054683133     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1804988     Document Type: Article

References (24)

1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60.
2. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124: 2458-73.
3. The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215-22.
4. IDF diabetes atlas. 8th ed. Brussels: International Diabetes Federation, 2017 (http://www.diabetesatlas.org).
5. Belch J, MacCuish A, Campbell I, et al. The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: a1840.
6. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008; 300: 2134-41.
7. Ikeda Y, Shimada K, Teramoto T, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA 2014; 312: 2510-20.
8. Fowkes FG, Price JF, Stewart MC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010; 303: 841-8.
9. Ajjan R, Storey RF, Grant PJ. Aspirin resistance and diabetes mellitus. Diabetologia 2008; 51: 385-90.
10. Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012; 379: 1602-12.
11. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010; 376: 1741-50.
12. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012; 379: 1591-601.
13. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007; 369: 1603-13.
14. The ASCEND Study Collaborative Group. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med. DOI1056/NEJMoa1804989.
15. Aung T, Haynes R, Barton J, et al. Cost-effective recruitment methods for a large randomised trial in people with diabetes: A Study of Cardiovascular Events iN Diabetes (ASCEND). Trials 2016; 17: 286.
16. Bowman L, Mafham M, Stevens W, et al. ASCEND: A Study of Cardiovascular Events iN Diabetes: characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes. Am Heart J 2018; 198: 135-44.
17. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335-71.
18. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976; 34: 585-612.
19. Rothwell PM, Cook NR, Gaziano JM, et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet 2018; 392: 387-99.
20. van Rooij FG, Kessels RPC, Richard E, De Leeuw F-E, van Dijk EJ. Cognitive impairment in transient ischemic attack patients: a systematic review. Cerebrovasc Dis 2016; 42: 1-9.
21. Bosch J, Eikelboom JW, Connolly SJ, et al. Rationale, design and baseline characteristics of participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial. Can J Cardiol 2017; 33: 1027-35.
22. Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017; 377: 1319-30.
23. Scally B, Emberson JR, Spata E, et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a metaanalysis of randomised trials. Lancet Gastroenterol Hepatol 2018; 3: 231-41.
24. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377: 31-41.